{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/609646d981e2cd483f8cf94c/6452d4e756fd69001143100b?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"11. Diagonal Bio AB: \"Our latest external study delivered extremly good results in line with our expectations\" - Jack Egelund Madsen, CEO","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/609646d981e2cd483f8cf94c/1702286263177-14a1fcfa4d378a93fb9c2babf0e7bc7e.jpeg?height=200","description":"<p><em>Jack Egelund Madsen, CEO at Diagonal Bio AB (publ), joins FinVoices to speak about the company and share the updates regarding Diagonal Bios latest and upcoming milestones.</em></p><p>&nbsp;</p><p><em>The latest results from the external&nbsp;study&nbsp;have&nbsp;proven that Diagonal Bios platform&nbsp;technology&nbsp;are delivering the quality, speed and sensitivity&nbsp;in line with our expectations, and more. Further, Jack explains the main focus for this year is to commercialize LAMPlify.</em></p><p>&nbsp;</p><p><em>// Diagonal Bio AB (publ) is a biotech company based in Lund. The company is developing two platforms developed on their own patented technology, PANVIRAL and LAMPlify, to detect&nbsp;genetic markers in genetic material (DNA or RNA based) regardless if this is originating from humans, animals, plants,&nbsp;viruses, bacteria and fungi. //</em></p><p>&nbsp;</p><p><em>FinVoices is operated by Impala Nordic.</em></p><p>&nbsp;</p><p><em>Disclaimer** Nothing said in the podcast is a buy or sell recommendation. This episode has been done on behalf of the company.</em></p>","author_name":"Impala Nordic"}